Related Experiment Video
Updated: Jan 8, 2026
07:46
Three-Dimensional Culture of Murine Colonic Crypts to Study Intestinal Stem Cell Function Ex Vivo
Published on: October 11, 2022
3.9K
Claudins proteins in brain tumors: expression patterns and therapeutic target
Adrianna Romanowicz1,2, Marta Łukaszewicz-Zając1, Barbara Mroczko1,2
1Department of Biochemical Diagnostics, Medical University of Bialystok, Bialystok, Poland.
Biochemia Medica
|December 16, 2025
Summary
Claudins (CLDNs), proteins forming tight junctions, are crucial in brain tumor development. Specific claudins show potential as biomarkers for diagnosing and treating central nervous system cancers like glioblastoma.
Area of Science:
- Neuroscience
- Oncology
- Cell Biology
Background:
- Tight junctions (TJs) maintain cell polarity and permeability, with TJ proteins like claudins (CLDNs) implicated in inflammation and cancer.
- Aggressive gliomas, including glioblastoma multiforme (GBM), are leading causes of brain cancer mortality, marked by recurrence and metastasis.
- CLDNs are integral to brain cancer pathophysiology, influencing tumor cell proliferation, invasion, and blood-brain barrier (BBB) integrity.
Purpose of the Study:
- To review the role of CLDNs in central nervous system (CNS) tumors, particularly malignant gliomas.
- To assess the diagnostic and prognostic significance of specific CLDNs in CNS malignancies.
- To explore CLDNs as potential therapeutic targets for brain cancers.
Main Methods:
- Literature review focusing on claudin expression and function in CNS tumors.
- Analysis of studies linking CLDNs to glioma progression, metastasis, and BBB disruption.
- Evaluation of the diagnostic and prognostic value of specific CLDNs in gliomas.
Main Results:
- CLDN3 and CLDN4 expression correlates with GBM growth, proliferation, and migration.
- Overexpression of CLDN3 is associated with glioma progression and metastasis.
- Reduced expression of CLDN1 and CLDN5 is observed in advanced gliomas.
Conclusions:
- CLDNs play a significant role in the development and progression of malignant gliomas.
- Specific CLDNs (e.g., CLDN3, CLDN4, CLDN1, CLDN5) exhibit potential as diagnostic and prognostic biomarkers for CNS tumors.
- CLDNs represent promising therapeutic targets for brain cancer treatment, warranting further clinical investigation.
Related Concept Videos
01:29Tight Junctions
6.8K
Tight junctions are molecular seals between cells that prevent the leaking of fluids, ions, and other small solutes across cavities and compartments in multicellular organisms. They are mainly composed of claudin and occludin transmembrane proteins, and other proteins such as tricellulin and JAM (junctional adhesion molecule). All these proteins are 4-pass transmembrane proteins, except JAM, which is a single-pass transmembrane protein belonging to the immunoglobulin superfamily. The...
6.8K
02:57Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
01:19Cadherins in Tissue Organization
3.8K
The cadherins are a superfamily of cell adhesion molecules comprising over 180 variants, with specific tissues expressing a particular combination of cadherin types. Cadherins generally exhibit homophilic binding; i.e., cadherins on one cell bind to cadherins of the same or closely related type on another cell. Thus, cells of the same type have a specific affinity to bind to each other and sort themselves into clusters to form tissues.
Cell Sorting During Development
Cell sorting plays an...
Cell Sorting During Development
Cell sorting plays an...
3.8K